There is less risk now than there was two weeks ago in my opinion. The safety aspect has not rendered the drug a non-starter. The efficacy question was unclear before the conference and remains unclear at this point, but there was nothing in the findings thus far that is a disqualifier. The PPS still reflects essentially a zero chance of success which logic indicates otherwise.